Richard Ransohoff

Richard Ransohoff

Company: Third Rock Ventures

Job title: Venture Partner


Panel Discussion: Are We Chasing the Wrong Phenomenon? 4:30 pm

• Do we have clinical proof of neuroinflammation as an effective target for neurodegeneration? Improving target identification logic: is neuroinflammation a cause or outcome? • Debating Biogen’s aducanumab implications on neuroinflammatory targets – standalone treatment or an add on? • Where are the challenges in neurodegeneration/neuroinflammation drug development compared to other disease areas like cardiovascular?…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.